Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | CPB1 | P15086 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22498188 | 0.93 | KDM4E (0.47) | KDM4EALDH1A1ALOX15GAAHSD17B10 | |
| SCHEMBL18161061 | 0.92 | KMT2A (0.46) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL30612395 | 0.92 | KDM4E (0.52) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| Hydrochloric Acid SCHEMBL11452770 | 0.91 | KMT2A (0.45) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| Hydrochloric Acid SCHEMBL11452778 | 0.90 | KDM4E (0.51) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL21246029 | 0.89 | CNR2 (0.39) | KDM4EGAAPOLBTYK2 | |
| SCHEMBL20689515 | 0.88 | TYK2 (0.41) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL20689221 | 0.88 | TYK2 (0.41) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL21258416 | 0.88 | TYK2 (0.41) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL20689625 | 0.87 | TYK2 (0.48) | KDM4EALDH1A1L3MBTL1POLBTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195513-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2025-06-19 | — | — | US | disclosed |
| EP-4536664-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BeiGene, Ltd. (KY) | 2025-04-16 | — | — | EP | disclosed |
| CN-119403805-A | Degradation of IRAK4 by conjugation of IRAK4 inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2025-02-07 | — | — | CN | disclosed |
| EP-3947378-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2024-11-13 | — | — | EP | disclosed |
| WO-2023237049-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-12-14 | — | — | WO | disclosed |
| US-20220296573-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2022-09-22 | — | — | US | disclosed |
| US-20220218679-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2022-07-14 | — | — | US | disclosed |
| US-20220194938-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2022-06-23 | — | — | US | disclosed |
| US-20220194938-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2022-06-23 | — | — | US | disclosed |
| EP-3947374-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2022-02-09 | — | — | EP | disclosed |
| CN-113646305-A | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | 加拉帕戈斯股份有限公司 | 2021-11-12 | — | — | CN | disclosed |
| US-10899772-B2 | IRAK4 modulators | GENENTECH, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| WO-2020200899-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020200900-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020200898-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020200899-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-10-08 | — | — | WO | disclosed |
| EP-3642201-A1 | ISOINDOLINONE DERIVATIVES AS IRAK4 MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-20200115383-A1 | IRAK4 MODULATORS | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| CN-110785418-A | Isoindolinone derivatives as IRAK4 modulators | 豪夫迈·罗氏有限公司 | 2020-02-11 | — | — | CN | disclosed |
| WO-2018234342-A1 | ISOINDOLINONE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218679-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | LTB4R2, LTC4S, CYSLTR1 | KDM4E 2741/4885ALDH1A1 499/4885ALOX15 77/4885 |
| US-20250195513-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | IRAK4, IRAK2, IRAK3 | KDM4E 335/4885ALDH1A1 3564/4885ALOX15 4519/4885 |
| US-20220296573-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | LTB4R2, LTC4S, LTB4R | KDM4E 2680/4885ALDH1A1 343/4885ALOX15 39/4885 |
| US-20220194938-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | LTB4R2, LTC4S, CYSLTR1 | KDM4E 2741/4885ALDH1A1 499/4885ALOX15 77/4885 |
| US-20200115383-A1 | IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | KDM4E 761/4885ALDH1A1 1862/4885ALOX15 4019/4885 |
| US-10899772-B2 | IRAK4 modulators | IRAK4, IRAK1, IRAK2 | KDM4E 761/4885ALDH1A1 1862/4885ALOX15 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.